What Is The Current and Historic Market Size Analysis Of The Pulmonary Embolism Market?
The pulmonary embolism market has seen considerable growth due to a variety of factors.
• In recent years, the pulmonary embolism market has seen significant expansion. The market, which is expected to rise from $2.03 billion in 2024 to $2.27 billion in 2025, has a compound annual growth rate (CAGR) of 11.9%.
The progress during the historic period has largely been as a result of anticoagulant therapies, ongoing research and clinical trials, an increase in awareness of pulmonary embolism, and vte prophylaxis.
What are the Market Size and Expected Growth Rates for the Pulmonary Embolism Market?
The pulmonary embolism market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to experience swift expansion in the coming years, the pulmonary embolism market is projected to rise to a value of $3.63 billion by 2029, reflecting a compound annual growth rate (CAGR) of 12.5%.
Factors contributing to this predicted growth during the forecast period include initiatives focused on targeted treatments, telemedicine and remote supervision, health equality, and global health. Emerging trends seen during the forecast period encompass the use of artificial intelligence in diagnosis, the development of new anticoagulants, response teams dedicated to pulmonary embolism, and a shift towards patient-centric care.
Which Key Drivers Are Propelling The Pulmonary Embolism Market's Growth?
The expected surge in the pulmonary embolism market can be attributed to the rising incidences of blood clots. A thrombus or a blood clot is a semi-solid or gel-like lump that forms inside a blood vessel. The occurrence of blood clots escalates the possibility of pulmonary embolism by hindering the flow of blood to the lungs. This blockage caused by the clot normally happens in the deep veins of the legs and heightens the risk of pulmonary embolism. As an example, Gavi, the Vaccine Alliance, an international group committed to enhancing access to new and lesser-used vaccines for children, featured an article in April 2022 revealing that post a 30-day exposure to COVID-19, the odds for severe lung clots rose 33 times, with a fivefold increase in the risk of deep vein thrombosis. Hence, the growing incidence of blood clots is fuelling the expansion of the pulmonary embolism market. The growth of the pulmonary embolism market is also expected to be driven by the increasing prevalence of cancer. Cancer is a collection of diseases that cause cells in the body to multiply abnormally and uncontrollably. The rise in the number of cancer cases elevates the risk of patients developing blood clots such as pulmonary embolism. This, in turn, increases the necessity for diagnostic procedures and treatments, including specific medications. For instance, the number of cancer cases reported by the American Cancer Society, a non-profit cancer advocacy organization based in the USA, rose to 2,001,140 in January 2024, marking a 2.19% increase from 1,958,310 cases in 2023. Therefore, the escalating prevalence of cancer is fuelling the development of the pulmonary embolism market.
What Are The Key Segments Within The Global Pulmonary Embolism Market?
The pulmonary embolism market covered in this report is segmented –
1) By Treatment: Medications, Mechanical Devices, Other Treatments
2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis
3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Medications: Anticoagulants, Thrombolytics
2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy
3) By Other Treatments: Surgical Embolectomy, Supportive Care
Pre-Book The Pulmonary Embolism Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Pulmonary Embolism Market?
Leading firms within the pulmonary embolism sector are investing in the creation of novel products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter as a way of securing a competitive edge. For example, Inari Medical Inc., located in the US, unveiled the Triever16 Curve catheter along with the RevCore thrombectomy catheter in June 2023. The new Triever16 Curve catheter is specifically created for peripheral thrombectomy and pulmonary embolism operations. This catheter offers excellent trackability and includes a pre-shaped curve for pinpointed aspiration. Its ingenuity lies in its design that facilitates easy access to larger and more potent 20F or 24F catheters. Meanwhile, the RevCore thrombectomy catheter is engineered to manage venous in-stent thrombosis. It is a mechanical thrombectomy tool that utilizes a nitinol basket for capturing and eliminating blood clots. These catheters also serve to enhance the safety and efficiency of pulmonary embolism processes.
Who Are the Key Players In The Pulmonary Embolism Market?
Major companies operating in the pulmonary embolism market are:
• Pfizer Inc.
• Johnson and Johnson Private Limited
• F. Hoffmann-La Roche Ltd.
• Merck And Co.Inc.
• Novartis AG
• Bayer AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• GSK PLC
• Abbott Laboratories
• AstraZeneca PLC
• Medtronic PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Mylan N.V.
• Daiichi Sankyo Co. Ltd.
• Boehringer Ingelheim International GmbH
• Mitsubishi Tanabe Pharma Corporation
• Genentech Inc.
• Hikma Pharmaceuticals PLC
• Aspen Pharmacare Holdings Limited
• Nippon Shinyaku Co. Ltd.
• Penumbra Inc.
• Fresenius Kabi AG
• Inari Medical Inc.
• AngioDynamics Inc.
• Otsuka Pharmaceutical Co. Ltd.
What Are The Regional Insights Into The Pulmonary Embolism Market?
North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
